SABCS HER2-Negative Spotlight | Conferences

Encouraging Findings With Ribociclib in HR+ Breast Cancer

December 21, 2016

Harold J. Burstein, MD, PhD, institute physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CDK 4/6 inhibitor ribociclib and its clinical activity in patients with hormone receptor (HR)-positive breast cancer.

Ribociclib Demonstrates Significant Benefit in Advanced Breast Cancer

December 17, 2016

Patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib (LEE011) combined with letrozole, a subgroup analysis of the randomized MONALEESA-2 trial showed.

Carboplatin Does Not Produce Greater Response Over Docetaxel in BRCA1 Methylated or Silenced TNBC

December 13, 2016

BRCA1 methylation or silencing does not predict for a better response to carboplatin over docetaxel in women with advanced triple-negative or BRCA1/2 breast cancer, according to results from a pre-planned biological analysis of the phase III TNT trial.

Continuous Low-Dose Ribociclib Active in Advanced Breast Cancer Causes Less Neutropenia

December 13, 2016

Continuous low-dose ribociclib shows preliminary activity, and has an acceptable safety profile as an alternative to intermittent ribociclib dosing when combined with fulvestrant in the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Lead neoMONARCH Researcher Provides Insight on Abemaciclib Potential in HR-Positive Breast Cancer

December 11, 2016

Recent promising findings with the neoadjuvant combination of the CDK4/6 inhibitor abemaciclib with anastrozole could lead to a novel therapeutic option for patients with hormone receptor (HR)–positive, HER2-negative early breast cancer.

Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

December 10, 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses what sets abemaciclib apart from other CDK 4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

AI Therapy May Put Breast Cancer Survivors at Risk For Cardiovascular Disease

December 10, 2016

Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.

Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast Cancer

December 09, 2016

Maura N. Dickler, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an ongoing clinical trial of the CDK4/6 inhibitor abemaciclib combined with the PD-L1 inhibitor pembrolizumab (Keytruda) for patients with hormone receptor (HR)-positive, HER2-negative breast cancer. She also sheds light on abemaciclib's unique mechanism of action.